In summary, currently no single marker fulfills all criteria for being an appropriate prognostic indicator for response to any anti-TNF treatment in IBD, and therefore the suggested biomarkers appear of limited clinical utility. This evidence concerns the gene TNF and inflammatory bowel disease.